J. M. Connors, Thrombophilia testing and venous thrombosis, vol.377, pp.1177-1787, 2017.

G. Ruiz-irastorza, M. J. Cuadrado, I. Ruiz-arruza, R. Brey, M. Crowther et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, vol.20, pp.206-218, 2011.

V. Pengo, G. Denas, G. Zoppellaro, S. P. Jose, A. Hoxha et al.,

A. Ghirarduzzi, A. Tosetto, I. Falanga, S. Martinelli, D. Testa et al., Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome, Blood, vol.132, pp.1365-1371, 2018.

A. Hoxha, A. Banzato, A. Ruffatti, and V. Pengo, Detection of lupus anticoagulant in the era of direct oral anticoagulants, Autoimmun. Rev, vol.16, pp.173-178, 2017.

M. E. Martinuzzo, L. H. Barrera, M. A. Adamo, J. C. Otaso, M. I. Gimenez et al., Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin, Int. J. Lab. Hematol, vol.36, 2014.

T. Flieder, M. Weiser, T. Eller, M. Dittrich, K. Bargen et al., Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants, Thromb. Res, vol.165, pp.101-106, 2018.

V. Pengo, A. Tripodi, G. Reber, J. H. Rand, T. L. Ortel et al., Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/ antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis, vol.7, pp.1737-1740, 2009.

D. Keeling, I. Mackie, G. W. Moore, I. A. Greer, and M. Greaves, Guidelines on the investigation and management of antiphospholipid syndrome, Br. J. Haematol, vol.157, pp.47-58, 2012.

P. A. Wayne, , 2014.

J. R. Genzen and J. L. Miller, Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing, Am. J. Clin. Pathol, vol.124, pp.586-593, 2005.

A. Hillarp, K. M. Gustafsson, L. Faxalv, K. Strandberg, F. Baghaei et al.,

M. Jacquemin, J. Toelen, J. Schoeters, I. Van-horenbeeck, I. Vanlinthout et al., The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation aassays for the diagnosis of hemostasis disorders, J. Thromb. Haemost, vol.13, pp.2087-2092, 2015.

M. Jacquemin, J. Toelen, L. Feyen, J. Schoeters, I. Van-horenbeeck et al., The adsorption of dabigatran is as efficient as addition of Idarucizumab to neutralize the drug in routine coagulation assays, Int. J. Lab. Hematol, vol.40, pp.442-447, 2018.

T. Exner, N. Michalopoulos, J. Pearce, R. Xavier, and M. Ahuja, Simple method for removing DOACs from plasma samples, Thromb. Res, vol.163, pp.117-122, 2018.

J. Favresse, B. Lardinois, L. Sabor, B. Devalet, J. Vandepapeliere et al.,

B. Lessire, H. Chatelain, J. Jacqmin, F. Douxfils, and . Mullier, Evaluation of the DOAC Stop procedure to overcome the Effect of DOACs on Several thrombophilia screening tests, Thromb. Haemost. Open, vol.2, pp.202-209, 2018.

C. Bouvy, J. Evrard, R. Siriez, F. Mullier, J. Douxfils et al., Removal of DOACs from plasma: performance comparison and pre-analytical considerations of three different devices, p.220, 2018.

I. Gouin-thibault, X. Delavenne, A. Blanchard, V. Siguret, J. E. Salem et al., Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin, J. Thromb

. Haemost, , vol.15, pp.273-283, 2017.

K. M. Devreese, T. L. Ortel, V. Pengo, and B. , De Laat, for the subcommittee on lupus anticoagulant/antiphospholipid antibodies, Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH, J. Thromb. Haemost, vol.16, pp.809-813, 2018.

R. C. Gosselin, D. M. Adcock, and J. Douxfils, An update of laboratory assessment of direct oral anticoagulants (DOACs), Int. J. Lab. Hematol, vol.41, pp.33-39, 2019.

R. Bonar, E. J. Favaloro, S. Mohammed, M. Ahuja, L. Pasalic et al., The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples, Pathology, vol.48, pp.60-71, 2016.

F. Ratzinger, M. Lang, S. Belik, P. Jilma-stohlawetz, K. G. Schmetterer et al., Lupus-anticoagulant testing at NOAC trough levels, Thromb. Haemost, vol.116, pp.235-240, 2016.

A. Godier, A. S. Dincq, A. C. Martin, A. Radu, I. Leblanc et al., Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study, Eur. Heart. J, vol.38, pp.2431-2439, 2017.

S. Testa, A. Tripodi, C. Legnani, V. Pengo, R. Abbate et al., START-Laboratory Register, Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillations: results observed in four anticoagulation clinics, Thromb. Res, vol.137, pp.178-183, 2016.

A. Antovic, E. M. Norberg, M. Berndtsson, A. Rasmuson, R. E. Malmström et al., Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting, Thromb. Haemost, vol.117, pp.1700-1704, 2017.

A. J. Goodwin and D. M. Adcock, Thrombophilia testing and venous thrombosis, vol.377, pp.2297-2298, 2017.

S. Miyakis, M. D. Lockshin, T. Atsumi, D. W. Branch, R. L. Brey et al.,

P. G. Derksen, T. De-groot, P. L. Koike, G. Meroni, Y. Reber et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome

. Haemost, , pp.295-306, 2006.

G. M. Van-os, B. De-laat, P. W. Kamphuisen, J. C. Meijers, and P. H. De-groot, Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time, J. Thromb. Haemost, vol.9, pp.1657-1659, 2011.

C. Pouplard, C. Vayne, C. Berthomet, E. A. Guery, B. Delahousse et al., The taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban, Int. J. Lab. Hem, vol.39, pp.60-63, 2016.

W. M. Halbmayer, G. Weigel, P. Quehenberger, J. Tomasits, A. C. Haushofer et al., Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests, Clin. Chem. Lab. Med, vol.50, pp.1601-1605, 2012.

R. Bonar, E. J. Favaloro, S. Mohammed, L. Pasalic, J. Sioufi et al., The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples, Pathology, vol.47, pp.355-364, 2015.